Common variable immunodeficiency (CVID) with granulomatous interstitial lung disease (GLILD) and SARS COVID-19 infection: case report and review of literature

Table 1 Treatment of CVID-GLILD with immunosuppressive therapy

Agent	RTX [17]	RTX + AZA [8]	RTX + MMF [8, 18]
Number of patients	3	29	15
Regimen used	375 mg/m² weekly × 4, then every 6 months	RTX: 375 mg/m² weekly × 4, then every 4–6 months + AZA: 1–2 mg/kg/day	RTX: 375 mg/m² weekly × 4, then every 4–6 months + MMF: 250–1000 mg twice daily (N = 14)
Regimen used	375 mg/m² weekly × 4, then every 6 months		RTX: 1 g × 2 dose 1 month apart + MMF: 1–2 g/day (N = 1)
Duration of follow up	24 months	16 months	16 months
Outcome	Improvement in CT chest and PFT	Improvement in CT chest and PFT, death = 1, relapse = 6	Improvement in CT chest and PFT, death = 1, relapse = 3
Adverse events	None reported	Reversible hepatotoxicity, intolerance, pneumonia	Pneumonia

ISSN: 1710-1492